Fosun International Ltd Has $25.61 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Fosun International Ltd lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 396,443 shares of the biopharmaceutical company’s stock after selling 53,718 shares during the quarter. Gilead Sciences accounts for 1.6% of Fosun International Ltd’s investment portfolio, making the stock its 13th biggest position. Fosun International Ltd’s holdings in Gilead Sciences were worth $25,606,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of GILD. Lenox Wealth Management Inc. increased its holdings in Gilead Sciences by 1.8% in the first quarter. Lenox Wealth Management Inc. now owns 9,059 shares of the biopharmaceutical company’s stock valued at $589,000 after buying an additional 156 shares during the last quarter. Vectors Research Management LLC grew its holdings in shares of Gilead Sciences by 6.3% during the fourth quarter. Vectors Research Management LLC now owns 2,651 shares of the biopharmaceutical company’s stock valued at $166,000 after purchasing an additional 157 shares during the last quarter. Creative Financial Designs Inc. ADV grew its holdings in shares of Gilead Sciences by 55.9% during the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 165 shares during the last quarter. Rathbone Brothers plc grew its holdings in shares of Gilead Sciences by 3.1% during the first quarter. Rathbone Brothers plc now owns 5,547 shares of the biopharmaceutical company’s stock valued at $361,000 after purchasing an additional 167 shares during the last quarter. Finally, Somerset Trust Co grew its holdings in shares of Gilead Sciences by 1.4% during the first quarter. Somerset Trust Co now owns 13,437 shares of the biopharmaceutical company’s stock valued at $874,000 after purchasing an additional 188 shares during the last quarter. Hedge funds and other institutional investors own 78.68% of the company’s stock.

Shares of NASDAQ GILD traded up $0.27 during mid-day trading on Monday, reaching $67.83. The company had a trading volume of 4,486,434 shares, compared to its average volume of 7,122,751. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $79.61. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53. The firm has a market capitalization of $87.13 billion, a PE ratio of 11.03, a PEG ratio of 3.15 and a beta of 1.12. The stock has a 50 day simple moving average of $66.26.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.53 by $0.23. The business had revenue of $5.28 billion for the quarter, compared to the consensus estimate of $5.29 billion. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. Gilead Sciences’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the business posted $1.48 earnings per share. Sell-side analysts forecast that Gilead Sciences, Inc. will post 6.6 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.72%. The ex-dividend date of this dividend was Thursday, June 13th. Gilead Sciences’s dividend payout ratio is presently 40.98%.

In other Gilead Sciences news, EVP Brett A. Pletcher sold 5,816 shares of the company’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $68.75, for a total transaction of $399,850.00. Following the completion of the sale, the executive vice president now directly owns 27,198 shares in the company, valued at $1,869,862.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $67.23, for a total transaction of $181,521.00. Following the sale, the director now owns 57,560 shares of the company’s stock, valued at $3,869,758.80. The disclosure for this sale can be found here. Insiders sold 19,484 shares of company stock valued at $1,290,142 over the last quarter. 0.20% of the stock is currently owned by corporate insiders.

Several equities analysts have recently commented on the company. UBS Group raised Gilead Sciences from a “neutral” rating to a “buy” rating and upped their target price for the company from $75.00 to $77.00 in a report on Wednesday, April 10th. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, April 9th. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Monday, May 6th. Finally, JPMorgan Chase & Co. restated a “buy” rating and issued a $87.00 target price on shares of Gilead Sciences in a research report on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $79.54.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: What are CEFs?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.